Curebound Appoints Paula Schneider and Richard Whittington to Board for Cancer Research Advancement
Curebound, a San Diego-based cancer research accelerator, has announced the appointment of Paula Schneider and Richard Whittington to its board of directors. Schneider, CEO of the Institute for Advancing Women’s Health and former president and CEO of Susan G. Komen, brings expertise in organizational leadership and women's health advocacy. Whittington, a long-time supporter and member of Curebound’s Founders Circle, offers experience in corporate strategy, AI, and finance modernization. These appointments aim to enhance Curebound's funding capabilities and accelerate the impact of its cancer research efforts, moving discoveries from laboratories to patients more quickly. 
